6zey
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Keap1 kelch domain bound to a small molecule inhibitor of the Keap1-Nrf2 protein-protein interaction== | ==Keap1 kelch domain bound to a small molecule inhibitor of the Keap1-Nrf2 protein-protein interaction== | ||
| - | <StructureSection load='6zey' size='340' side='right'caption='[[6zey]]' scene=''> | + | <StructureSection load='6zey' size='340' side='right'caption='[[6zey]], [[Resolution|resolution]] 1.80Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6ZEY OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6ZEY FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6zey]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6ZEY OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6ZEY FirstGlance]. <br> |
| - | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6zey FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6zey OCA], [https://pdbe.org/6zey PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6zey RCSB], [https://www.ebi.ac.uk/pdbsum/6zey PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6zey ProSAT]</span></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene>, <scene name='pdbligand=QGZ:5-cyclopropyl-1-[3-(phenylsulfonylamino)phenyl]pyrazole-4-carboxylic+acid'>QGZ</scene></td></tr> |
| + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">Keap1, Inrf2, Kiaa0132 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=10090 LK3 transgenic mice])</td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6zey FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6zey OCA], [https://pdbe.org/6zey PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6zey RCSB], [https://www.ebi.ac.uk/pdbsum/6zey PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6zey ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | == Function == | ||
| + | [[https://www.uniprot.org/uniprot/KEAP1_MOUSE KEAP1_MOUSE]] Retains NFE2L2/NRF2 in the cytosol. Functions as substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1. Targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression. May also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome (By similarity).<ref>PMID:9887101</ref> <ref>PMID:12682069</ref> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Targeting the protein-protein interaction (PPI) between nuclear factor erythroid 2-related factor 2 (Nrf2) and Kelch-like ECH-associated protein 1 (Keap1) is a potential therapeutic strategy to control diseases involving oxidative stress. Here, six classes of known small-molecule Keap1-Nrf2 PPI inhibitors were dissected into 77 fragments in a fragment-based deconstruction reconstruction (FBDR) study and tested in four orthogonal assays. This gave 17 fragment hits of which six were shown by X-ray crystallography to bind in the Keap1 Kelch binding pocket. Two hits were merged into compound 8 with a 220-380-fold stronger affinity (Ki = 16 muM) relative to the parent fragments. Systematic optimization resulted in several novel analogues with Ki values of 0.04-0.5 muM, binding modes determined by X-ray crystallography, and enhanced microsomal stability. This demonstrates how FBDR can be used to find new fragment hits, elucidate important ligand-protein interactions, and identify new potent inhibitors of the Keap1-Nrf2 PPI. | ||
| + | |||
| + | Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds.,Pallesen JS, Narayanan D, Tran KT, Solbak SMO, Marseglia G, Sorensen LME, Hoj LJ, Munafo F, Carmona RMC, Garcia AD, Desu HL, Brambilla R, Johansen TN, Popowicz GM, Sattler M, Gajhede M, Bach A J Med Chem. 2021 Apr 5. doi: 10.1021/acs.jmedchem.0c02094. PMID:33818106<ref>PMID:33818106</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 6zey" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| - | [[Category: Bach A]] | + | [[Category: Lk3 transgenic mice]] |
| - | [[Category: Gajhede M]] | + | [[Category: Bach, A]] |
| - | [[Category: Narayanan D]] | + | [[Category: Gajhede, M]] |
| + | [[Category: Narayanan, D]] | ||
| + | [[Category: Keap1]] | ||
| + | [[Category: Nrf2]] | ||
| + | [[Category: Oxidative stress]] | ||
| + | [[Category: Peptide binding protein]] | ||
| + | [[Category: Small molecule complex]] | ||
Revision as of 09:02, 5 May 2021
Keap1 kelch domain bound to a small molecule inhibitor of the Keap1-Nrf2 protein-protein interaction
| |||||||||||
